Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m) convertedTranchesRegionDate
HYC
HLTH
PRCD
CHEPDE
Cheplapharm Arzneimittel GmbH$1,176
2EMEA
Oct 8, 2020
currency
EUR
size (m)
575.000
maturity
Jan 15, 2028
type
Fixed
tenor
7.250
call
3.25
registration
144A/Reg S
benchmark
-
ranking
-
moody's
B2
s&p
B
fitch
BB-
size description
-
re-open/tap
No
ipt
mid-high 4s
ipt-pxd
-
guidance
4.50% area
spread
504
coupon
4.375%
spread set
-
price
100.00000
yield
4.375%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
-
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
-
passive leads
-
co-managers
-
coordinating managers
-
currency
USD
size (m)
500.000
maturity
Jan 15, 2028
type
Fixed
tenor
7.250
call
3.25
registration
144A/Reg S
benchmark
-
ranking
-
moody's
B2
s&p
B
fitch
BB-
size description
-
re-open/tap
No
ipt
6% area
ipt-pxd
-
guidance
5.75% area, revised 5.50%-5.625%
spread
493
coupon
5.500%
spread set
-
price
100.00000
yield
5.500%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
-
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
-
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
Registration: 144A/Reg S; Comments: EUR575m (from EUR400m minimum size) due 01/15/28 (7.25y). NC3.25 (01/15/24) (MWC B+50bp), Then at 102.187, 101.094, 100. Equity claw: 3.25y 40% at 104.375. Special call: 10% per year the first 3.25 years at 103. Reg S ISIN: XS2243548273. IPT mid-to-high 4s. Px talk: 4.50% area. Launched: EUR575m at 4.375%. Priced: 4.375% at 100. +504bp vs DBR 5.625% 01/04/28.; Registration: 144A/Reg S; Comments: USD500m (from USD500m minimum size) due 2028 (7.25y). NC3.25 (MWC T+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT 6% area. Px talk: 5.75% area. Revised price talk: $500m at 5.50%-6.625%.;
Deal Comments
Cheplapharm Arzneimittel GmbH (CHEPDE) EUR1bn equivalent (EUR/US$) 144A/Reg S sr sec 1st lien notes 2-part. B2/B/BB- (negative/stable/stable). Via JPM/DB joint glocos/CS/HSBC joint books. No reg rights. List ISE. NY law. - EUR575m (from EUR400m minimum size) due 2029 (7.25y). NC3.25 (MWC B+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT mid-to-high 4s. Px talk: 4.50% area. Launched: EUR575m at 4.375%. - USD500m (from USD500m minimum size) due 2028 (7.25y). NC3.25 (MWC T+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT 6% area. Px talk: 5.75% area. Revised price talk: $500m at 5.50%-6.625%. Roadshow 10/05-07 (European investor call at 11am UKT 10/05, US investor call at 12:30pm NYT 10/05). EUR books closed at 10am UKT 10/08. US books now close at 10am 10/08 (originally closing at 5pm NYT 10/07). Pricing 10/08. UOP: along with EUR90m cash on hand and a EUR50m revolver drawdown, to fund acquisitions (cardiology portfolio form Sanofi for EUR93m, portfolio of 4 products from LEO Pharma for EUR302m, portfolio of products from Takeda for EUR475m and Rivotril from Roche for EUR260m). Biz: specialty pharmaceuticals. HQ: Greifswald, Germany.

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.